10-Q: Longeveron Faces Delisting Risk Amid Rising Losses

Longeveron Inc. reported increased net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, while also facing a Nasdaq delisting notice.

Summary

• Net loss for the nine months ended September 30, 2025, increased by 45% to $17.3 million, compared to $11.9 million for the same period in 2024.
• Total revenues decreased by 53% to $0.8 million for the nine months ended September 30, 2025, down from $1.8 million in 2024, primarily due to reduced demand for contract manufacturing and lower clinical trial revenue.
• Cash and cash equivalents stood at $9.2 million as of September 30, 2025, down from $19.2 million at December 31, 2024.
• The company anticipates its existing cash will fund operations only until late in the first quarter of 2026, indicating a need for additional financing.
• A Nasdaq notice was received on September 22, 2025, for not meeting the $1.00 minimum bid price requirement, with a compliance period until March 23, 2026.
• The ELPIS II Phase 2b clinical trial for Hypoplastic Left Heart Syndrome (HLHS) reached full enrollment on June 24, 2025, with top-line results expected in Q3 2026.
• The FDA approved the Investigational New Drug (IND) application for laromestrocel as a potential treatment for pediatric Dilated Cardiomyopathy (DCM) in July 2025, allowing direct progression to a Phase 2 pivotal registrational clinical trial in 2026, subject to financing.
• Laromestrocel for mild Alzheimer's disease (AD) received Regenerative Medicine Advanced Therapeutics (RMAT) and Fast Track designations in July 2024, and a positive Type B Meeting with the FDA in March 2025 supports a single, pivotal, seamless adaptive Phase 2/3 clinical trial.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including a significant increase in net loss, declining revenue, a 'going concern' warning, and a Nasdaq delisting notice. While there is promising clinical progress and FDA designations for its product candidates, the immediate financial instability and high capital requirements present substantial risks. The need for immediate and significant capital raises, coupled with the delisting threat, overshadows the clinical positives for the near term.

Positives

• The ELPIS II Phase 2b clinical trial for Hypoplastic Left Heart Syndrome (HLHS) has completed full enrollment as of June 24, 2025, a significant milestone towards potential regulatory approval.
• Laromestrocel for mild Alzheimer's disease (AD) received Regenerative Medicine Advanced Therapeutics (RMAT) and Fast Track designations from the FDA in July 2024, highlighting its potential to address an unmet medical need.
• A positive Type B Meeting with the FDA in March 2025 for mild AD supports advancing laromestrocel to a single, pivotal, seamless adaptive Phase 2/3 clinical trial, with the FDA agreeing to consider a Biologics License Application (BLA) based on positive interim results.
• The FDA approved the Investigational New Drug (IND) application for laromestrocel as a potential treatment for pediatric Dilated Cardiomyopathy (DCM) in July 2025, allowing direct progression to a Phase 2 pivotal registrational clinical trial.
• The company has received approximately $16.3 million in grant awards since 2016, with $0.3 million received as a Milestone 1 Award in the XPRIZE Healthspan competition during the nine months ended September 30, 2025.

Negatives

• Net loss increased by 45% to $17.3 million for the nine months ended September 30, 2025, compared to $11.9 million in the prior year period.
• Total revenues decreased by 53% to $0.8 million for the nine months ended September 30, 2025, primarily due to a 76% reduction in contract manufacturing revenue and a 36% decrease in clinical trial revenue.
• Cash and cash equivalents decreased significantly to $9.2 million as of September 30, 2025, from $19.2 million at December 31, 2024.
• The company has incurred recurring losses since inception and has an accumulated deficit of $126.9 million as of September 30, 2025.
• There is substantial doubt about the company's ability to continue as a going concern, as existing cash is only anticipated to fund operations until late in the first quarter of 2026.
• The company received a Nasdaq notice on September 22, 2025, for failing to meet the $1.00 minimum bid price requirement, risking delisting.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and insufficient cash to meet minimum expenditure commitments for one year.
• The company's Class A Common Stock is at risk of delisting from The Nasdaq Capital Market if it fails to regain compliance with the $1.00 minimum bid price requirement by March 23, 2026, or any extended period.
• A prolonged U.S. federal government shutdown could delay regulatory communications, clinical-site activation, data submission schedules, grant funding, and financing transactions, adversely impacting operations and clinical development.
• The company's CMC readiness and ability to manufacture for commercialization may be delayed or unsuccessful, impacting the clinical and commercial success of product candidates.
• Clinical development efforts for product candidates may fail at any stage, despite promising early results or designations.
• The company will need to raise additional capital, which may result in significant dilution to current stockholders or unfavorable terms for debt financing or collaborations.
• There is no assurance that future financing will be attained at favorable terms or at all, which could necessitate a material revision of current operational plans.

Future Outlook

The company anticipates its existing cash and cash equivalents will enable it to fund operating expenses and capital expenditure requirements late into the first quarter of 2026. It expects increased spending and additional capital investments to support initiatives, including a potential Biologics License Application (BLA) filing for HLHS in 2027 if the ELPIS II trial is successful. The company intends to seek additional financing through capital raises, non-dilutive funding options, and commercial partnering across all indications, including a Phase 2 pivotal registrational clinical trial for DCM in 2026, subject to obtaining necessary financing. Strategic collaborations and partnerships are being pursued for the advancement of laromestrocel in Alzheimer's disease.

Management Comments

• "We currently anticipate our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements late into the first quarter of 2026, based on our current operating budget and cash flow forecast."
• "We expect that our current operating plan will require increased spending and additional capital investments to support these initiatives and we intend to seek additional financing through capital raises, non-dilutive funding options, and commercial partnering across all indications."
• "There can be no assurance we will be able to attain future financing at terms favorable to us or at all. In the event we are unable to attain the financing needed, we will need to materially revise our current operational plans."
• "The Company has prepared a cash flow forecast which indicates that it does not have sufficient cash to meet its minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore needs to raise additional funds to continue as a going concern. As a result, there is substantial doubt about the Company’s ability to continue as a going concern."
• "Our overarching objective is to advance laromestrocel through strategic collaborations and partnerships, with the goal of addressing the significant unmet medical need in AD."

Industry Context

Longeveron operates in the highly competitive and rapidly changing clinical-stage biotechnology sector, focusing on cellular therapies for aging-related and life-threatening conditions. Its lead candidate, laromestrocel, targets significant unmet medical needs like HLHS, AD, and pediatric DCM. The company's strategy to pursue commercial manufacturing through a third-party CDMO aligns with a common industry trend for smaller biotech firms to outsource large-scale production, optimizing cost and timeline. The receipt of FDA designations (RMAT, Fast Track, Orphan Drug, Rare Pediatric Disease) for its candidates positions it favorably within the regulatory landscape, indicating potential for expedited development and market exclusivity, which is crucial for emerging biotechs.

Comparison to Industry Standards

• The company's strategy to use a third-party CDMO for commercial manufacturing for HLHS is a common practice among clinical-stage biotech companies, allowing them to avoid the significant capital expenditure and operational complexities of building and maintaining commercial-scale facilities. This is comparable to how many smaller biotechs, such as those developing gene therapies or complex biologics, leverage specialized contract manufacturers like Lonza or Catalent to scale production for late-stage trials and commercial launch.
• The FDA's agreement to consider a BLA for mild AD based on positive interim trial results from a single pivotal study is a significant regulatory acceleration, similar to pathways granted to other innovative therapies for serious conditions, such as Biogen's Aduhelm for AD (though its approval was controversial) or various oncology drugs that received accelerated approval based on surrogate endpoints.
• The company's accumulated deficit of $126.9 million and recurring operating losses are typical for clinical-stage biotechnology companies, which require substantial R&D investment over many years before potential product commercialization. This financial profile is common among peers like Athersys (ATHX) or Mesoblast (MESO), which are also developing allogeneic cell therapies and have faced similar challenges in achieving profitability and securing long-term funding.

Management Changes

Legal Proceedings

• As of September 30, 2025, the company is not aware of any legal proceedings or material developments requiring disclosure.

Related Party Transactions

• Consulting services agreement with Dr. Joshua Hare (CSO) for $265,000 annually, with deferred payments for 2024 and 2025 to be paid in February 2027.
• Stock option agreements with Dr. Joshua Hare (CSO) on March 4, 2025, April 11, 2025, and July 1, 2025, as part of a Cash-for-Equity Program, settling accrued consulting fees and performance bonus.
• Grant of options to Dr. Joshua Hare (CSO) on July 15, 2025, for 109,000 shares as part of his annual compensation package.
• Exclusive License Agreement with UM (where CSO developed technology) for Aging-related Frailty Mesenchymal Stem Cell (MSC) technology rights, requiring royalties and milestone payments.
• Additional Exclusive License Agreement with UM for UMP-144 technology rights, requiring milestone payments.
• Exclusive license agreement with JMH MD Holdings, LLC (an affiliated entity of Dr. Joshua Hare) for CD271 cellular therapy technology, requiring running royalties on net sales.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity financings, as well as the potential for delisting from Nasdaq, which could reduce liquidity and adversely affect share value.
• Employees are impacted by equity-based compensation plans and potential severance, as well as the overall financial stability of the company.
• Customers of contract manufacturing services have seen a substantial reduction in activities, indicating a decrease in this revenue stream.
• Patients with HLHS, AD, and pediatric DCM could potentially benefit from the company's investigational therapies if clinical trials are successful and regulatory approvals are obtained, offering hope for unmet medical needs.
• Creditors and suppliers may face increased risk due to the company's 'going concern' warning and reliance on future financing.

Next Steps

• Monitor the closing bid price of Class A common stock and assess options to regain compliance with the Nasdaq Minimum Bid Price Requirement by March 23, 2026.
• Anticipate top-line trial results for the ELPIS II Phase 2b study in HLHS in the third quarter of 2026.
• Potentially file a Biologics License Application (BLA) with the FDA for HLHS in 2027 if the ELPIS II trial is successful.
• Prepare and initiate a Phase 2 pivotal registrational clinical trial for pediatric DCM in 2026, subject to obtaining necessary financing.
• Continue in-depth analyses of Alzheimer's disease (AD) data to refine the clinical development strategy and pursue strategic collaborations and partnerships for AD advancement.
• Advance BLA-enabling Chemistry, Manufacturing and Controls (CMC) activities, including process and analytical method validation planning and commercial production planning through a third-party CDMO.
• Seek additional financing through capital raises, non-dilutive funding options, and commercial partnering across all indications.
• Continue to enroll patients in the Frailty and Cognitive Impairment registry trials in The Bahamas and plans to launch an Osteoarthritis registry trial.
• Expand the intellectual property portfolio through ongoing research and development efforts.

Key Dates

Recommendation

The company faces critical financial distress, evidenced by a substantial increase in net loss, declining revenues, a 'going concern' warning, and a Nasdaq delisting notice. While the clinical pipeline shows promise with multiple FDA designations and ongoing trials, the immediate and severe liquidity issues, coupled with the high risk of delisting and significant future dilution from necessary capital raises, present an unfavorable risk-reward profile for investors. The financial instability outweighs the long-term clinical potential in the near to medium term, making a 'sell' recommendation appropriate for a seasoned investor.

Keywords

Longeveron, LGVN, Biotechnology, Cell Therapy, Laromestrocel, HLHS, Hypoplastic Left Heart Syndrome, Alzheimer's Disease, AD, Dilated Cardiomyopathy, DCM, Clinical Trials, FDA, RMAT, Orphan Drug, Fast Track, Nasdaq Delisting, Going Concern, Capital Raise, SEC Filing, 10-Q